Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80
Ashkan Shahbandi, Fang-Yen Chiu, Nathan Ungerleider, Raegan Kvadas, Zeinab Mheidly, Meijuan J.S. Sun, Di Tian, Daniel A. Waizman, Ashlyn Y. Anderson, Heather L. Machado, Zachary F. Pursell, Sonia G. Rao, James G. Jackson
Topics & Concepts
Immune systemCancer researchBiologyBreast cancerPopulationChemotherapyImmunologyCD80CancerMedicineCytotoxic T cellIn vitroGeneticsCD40Environmental healthCancer Immunotherapy and BiomarkersImmune cells in cancerImmunotherapy and Immune Responses